Hizawa N, Maeda Y, Konno S, Fukui Y, Takahashi D, Nishimura M
First Department of Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Clin Exp Allergy. 2006 Jul;36(7):872-6. doi: 10.1111/j.1365-2222.2006.02413.x.
We previously detected a promoter polymorphism (- 109C/T) in the gene for the beta-chain of the high-affinity receptor for IgE (FCER1B), which was associated with total serum IgE levels but not with asthma in a Japanese population. A genetic interaction is biologically plausible between FcepsilonRI-beta and the plasminogen activator inhibitor 1 (PAI-1), which is highly expressed in mast cells in asthmatics and plays an essential role in airway remodelling. We hypothesized that FCER1B promoter polymorphisms, by modifying the intensity of mast cell activation signals, modulate the genetic effects of a functional 4G/5G polymorphism in the PAI-1 gene on asthma. OBJECTICIVE: To examine whether FCER1B promoter polymorphisms (- 109C/T and - 654C/T) influence the genetic effects of the functional polymorphism (4G/5G) at the PAI-1 promoter region on asthma susceptibility using a case-control analysis.
Subjects (374 asthmatic patients and 374 non-asthmatic controls) were divided into combined genotype groups based on the presence of FCER1B - 109TT and - 654CC genotypes and the PAI-1 4G allele. Logistic regression analysis was used to estimate adjusted odds ratios for asthma associated with the different genotype groups.
Individuals homozygous for the FCER1B - 109T/ - 654C haplotype and the PAI - 1 5G allele had a reduced susceptibility to asthma; the odds ratio for the development of asthma was 0.20 (95% confidence interval, 0.084 - 0.46; P = 0.00015) for them, compared with individuals also homozygous for the - 109T/- 654C haplotype at FCER1B but carrying the 4G allele at PAI-1. The regression model also showed an interaction of the PAI-1 4G/5G genotype with the FCER1B-109C/T (P for interaction = 0.0017) or FCER1B-654C/T (P for interaction = 0.031) on asthma.
The present findings suggest a synergistic interaction between FCER1B and PAI-1 genes in asthma susceptibility.
我们之前在IgE高亲和力受体β链基因(FCER1B)中检测到一种启动子多态性(-109C/T),在日本人群中,该多态性与血清总IgE水平相关,但与哮喘无关。FcεRI-β与纤溶酶原激活物抑制剂1(PAI-1)之间存在生物学上合理的基因相互作用,PAI-1在哮喘患者的肥大细胞中高表达,并且在气道重塑中起重要作用。我们推测,FCER1B启动子多态性通过改变肥大细胞激活信号的强度,调节PAI-1基因功能性4G/5G多态性对哮喘的遗传效应。目的:采用病例对照分析,研究FCER1B启动子多态性(-109C/T和-654C/T)是否影响PAI-1启动子区域功能性多态性(4G/5G)对哮喘易感性的遗传效应。
根据是否存在FCER1B -109TT和-654CC基因型以及PAI-1 4G等位基因,将研究对象(374例哮喘患者和374例非哮喘对照)分为合并基因型组。采用逻辑回归分析估计不同基因型组与哮喘相关的调整比值比。
FCER1B -109T/-654C单倍型和PAI-1 5G等位基因纯合的个体对哮喘的易感性降低;与FCER1B的-109T/-654C单倍型纯合但PAI-1携带4G等位基因的个体相比,他们患哮喘的比值比为0.20(95%置信区间,0.084 - 0.46;P = 0.00015)。回归模型还显示,PAI-1 4G/5G基因型与FCER1B-109C/T(交互作用P = 0.0017)或FCER1B-654C/T(交互作用P = 0.031)对哮喘存在交互作用。
目前的研究结果提示FCER1B和PAI-1基因在哮喘易感性方面存在协同相互作用。